https://flcube.com/hengrui-pharmaceuticals-wins-nmpa-clinical-trial-approval-for-shr-1179-first-in-class-biological-candidate-for-weight-management/Insight, China's Pharmaceutical Industryen2026-09-08T14:41:20+08:00Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management https://flcube.com/hualan-bio-wins-nmpa-clinical-trial-approval-for-novel-influenza-mrna-vaccine-chinas-vaccine-major-pushes-into-mrna-platform/Insight, China's Pharmaceutical Industryen2026-09-08T14:13:42+08:00Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform https://flcube.com/suzhou-asiflyer-biotechnology-secures-exclusive-worldwide-license-from-shanghaitech-university-for-ai-designed-recombinant-botulinum-toxin-patent/Insight, China's Pharmaceutical Industryen2026-09-08T14:02:50+08:00Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent https://flcube.com/sun-novo-pharmaceutical-and-deepmed-technology-sign-strategic-pact-on-ai-driven-drug-rd-building-closed-loop-ai-design-wet-lab-validation-discovery-system/Insight, China's Pharmaceutical Industryen2026-09-08T12:57:32+08:00Sun-Novo Pharmaceutical and DeepMed Technology Sign Strategic Pact on AI‑Driven Drug R&D – Building Closed‑Loop “AI Design + Wet‑Lab Validation” Discovery System https://flcube.com/liaocheng-university-and-shanghai-maiboxing-biotechnology-sign-rmb-19-million-pact-to-co-develop-lcugz1007-next-generation-e-pdc-probody-drug-conjugate/Insight, China's Pharmaceutical Industryen2026-09-08T12:53:10+08:00Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate https://flcube.com/clinical-stage-biopharma-revelyx-bio-launches-with-exclusive-global-license-for-yy003-ready-to-use-recombinant-botulinum-toxin-type-a/Insight, China's Pharmaceutical Industryen2026-09-08T12:48:18+08:00Clinical‑Stage Biopharma Revelyx Bio Launches with Exclusive Global License for YY003 – Ready‑to‑Use Recombinant Botulinum Toxin Type A https://flcube.com/eton-pharmaceuticals-licenses-ausons-timolol-gel-asn001-for-north-america-potential-first-topical-therapy-for-infantile-hemangioma-in-the-u-s/Insight, China's Pharmaceutical Industryen2026-09-08T12:44:31+08:00Eton Pharmaceuticals Licenses Auson’s Timolol Gel ASN001 for North America – Potential First Topical Therapy for Infantile Hemangioma in the U.S. https://flcube.com/china-medical-system-licenses-leios-therapeutics-injectable-fat-reduction-therapy-10xb-101-in-greater-china-alongside-strategic-equity-investment/Insight, China's Pharmaceutical Industryen2026-09-08T12:39:03+08:00China Medical System Licenses Leios Therapeutics’ Injectable Fat‑Reduction Therapy 10XB‑101 in Greater China, Alongside Strategic Equity Investment https://flcube.com/china-biotechs-panboron-bnct-hospital-signs-strategic-pact-with-oncocare-cancer-centre-hk-launching-cross-border-bnct-oncology-cooperation/Insight, China's Pharmaceutical Industryen2026-09-08T12:33:07+08:00China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation https://flcube.com/guangdong-taienkang-completes-capital-increase-in-procapzoom-secures-exclusive-china-rights-to-world-first-ocular-surface-cell-therapy-sz018/Insight, China's Pharmaceutical Industryen2026-09-08T12:24:46+08:00Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018 https://flcube.com/hepabio-therapeutics-raises-series-a-strategic-funding-from-triapex-to-advance-organoid-technology-and-next-generation-drug-rd-systems/Insight, China's Pharmaceutical Industryen2026-09-07T12:46:44+08:00HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems https://flcube.com/nmpa-accepts-medilink-therapeutics-nda-for-tam-peli-self-developed-b7-h3-targeting-adc-for-relapsed-small-cell-lung-cancer/Insight, China's Pharmaceutical Industryen2026-09-07T12:41:23+08:00NMPA Accepts MediLink Therapeutics’ NDA for Tam‑Peli, Self‑Developed B7‑H3‑Targeting ADC for Relapsed Small Cell Lung Cancer https://flcube.com/insilico-medicine-and-mobidrop-sign-strategic-partnership-to-advance-ai-ready-single-cell-data-for-drug-discovery/Insight, China's Pharmaceutical Industryen2026-09-07T12:38:26+08:00Insilico Medicine and MobiDrop Sign Strategic Partnership to Advance AI‑Ready Single‑Cell Data for Drug Discovery https://flcube.com/innovent-biologics-suzhou-base-passes-ema-on-site-inspection-securing-eu-gmp-certification-on-first-attempt/Insight, China's Pharmaceutical Industryen2026-09-07T12:34:07+08:00Innovent Biologics’ Suzhou Base Passes EMA On‑Site Inspection, Securing EU GMP Certification on First Attempt https://flcube.com/santens-atropine-eye-drops-ryjusea-wins-nda-acceptance-from-chinas-nmpa-for-myopia-progression/Insight, China's Pharmaceutical Industryen2026-09-07T12:29:45+08:00Santen’s Atropine Eye Drops RYJUSEA Wins NDA Acceptance From China’s NMPA for Myopia Progression https://flcube.com/anglikang-pharmaceuticals-terminates-affinity-partnership-for-imd-1005-novel-tumor-microenvironment-activated-cd47-antibody/Insight, China's Pharmaceutical Industryen2026-09-07T12:23:51+08:00Anglikang Pharmaceuticals Terminates Affinity Partnership for IMD‑1005, Novel Tumor Microenvironment‑Activated CD47 Antibody https://flcube.com/jenscares-lux-valve-plus-wins-hong-kong-approval-expanding-global-footprint-of-transcatheter-tricuspid-valve-replacement-system/Insight, China's Pharmaceutical Industryen2026-09-07T12:12:03+08:00Jenscare’s LuX‑Valve Plus Wins Hong Kong Approval, Expanding Global Footprint of Transcatheter Tricuspid Valve Replacement System https://flcube.com/tennor-therapeutics-reports-positive-phase-iia-top-line-results-for-tnp-2092-in-prosthetic-joint-infection-first-in-class-triple-target-candidate-advances-to-p/Insight, China's Pharmaceutical Industryen2026-09-07T12:05:51+08:00TenNor Therapeutics Reports Positive Phase IIa Top‑Line Results for TNP‑2092 in Prosthetic Joint Infection; First‑in‑Class Triple‑Target Candidate Advances to Phase IIb